Release date: 2008-04-11

A groundbreaking technique using endoscopes for harvesting saphenous vein grafts has been successfully implemented in coronary artery bypass surgery. Dr. Liu Jincheng from the Department of Cardiac Surgery at Xijing Hospital, Fourth Military Medical University, and his team have been applying this endoscopic method for six years. Their research project demonstrated excellent clinical outcomes, earning the second prize in the 2007 military medical achievements. Coronary artery bypass grafting (CABG) is one of the most effective treatments for coronary heart disease. Since 1998, foreign researchers have used endoscopic techniques to collect the great saphenous vein for CABG. In April 2000, Dr. Liu and his colleagues began using the VASOVIEW endoscope to harvest the saphenous vein for CABG, successfully performing the procedure on 196 patients with positive results. Compared to traditional methods, endoscopic vein collection offers less trauma, reduced pain, and faster recovery. The incidence of postoperative lower limb complications was 66% lower than that of traditional incisions, especially in diabetic patients. Patients also experienced a reduction of 1.1 days in average walking time compared to those in the conventional group. The study revealed that endoscopic harvesting significantly improved the quality of venous grafts compared to traditional techniques. Histological analysis showed that the endoscopically harvested vessels were more intact, with no significant damage to the vessel walls. Additionally, the researchers explored the effects of PDGFR-β antisense oligodeoxynucleotides on vascular restenosis. They developed an in vitro model of vascular smooth muscle cell proliferation and found that these oligonucleotides inhibited SMC proliferation and migration while promoting apoptosis. Beyond technical improvements, the team introduced new approaches to postoperative care in CABG procedures. They focused on psychological support for patients with coronary heart disease, reducing stress and improving recovery. They also proposed innovative methods for early leg activity after endoscopic vein collection, enhancing patient outcomes. This advancement marks a significant step forward in minimally invasive cardiac surgery. —— China Pharmaceutical 123 Network

Sarms Liquid

What is S-23?

S-23 demonstrates a markedly strong bond to androgen receptors

S-23 is an modern selective androgen receptor modulator (SARM) with the added interest in its potential for male hormonal contraceptive. It binds to the androgen receptor more strongly than older compounds such as Andarine with a Ki of 1.7nM, and in animal studies it showed both a good ratio of anabolic to androgenic effects, and dose-dependent suppression of spermatogenesis with spontaneous recovery after cessation of research.

Added value for research with pronounced suppression of spermatogenesis. Not for human consumption.

S-23 Function

S-23 not only boosted muscle mass, but also reduced fat mass, as studied. SARMs have a bit of a 'soft' image in the doping world. They don't stimulate muscle growth in the way that anabolic Steroids do, but many users say that they are safer.

There are no studies yet that confirm this suspicion. But that S23 is not one of the safer SARMs - we'd be willing to wager a bottle of BCAAs on that.

S23 halts the production of sperm in the testes. In fact it does this so well that the researchers suspect S23 might be a good candidate for a male contraceptive. If this is the case it would probably have to be part of a cocktail that also contains an estradiol analogue, the researchers discovered. The lab animals lost their libido when they were given S23 on its own, and only recovered this when they were given estradiol benzoate together with the S23.